SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024 08:55 ET
|
SciSparc Ltd
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash TEL AVIV, Israel, Aug. 28,...
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 23, 2024 16:09 ET
|
SciSparc Ltd
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel TEL...
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024 08:12 ET
|
SciSparc Ltd
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of...
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 19, 2024 16:11 ET
|
SciSparc Ltd
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market TEL AVIV, Israel,...
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 16, 2024 16:30 ET
|
SciSparc Ltd
SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met TEL AVIV, Israel, Aug. 16, 2024 (GLOBE...
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024 16:53 ET
|
SciSparc Ltd
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its...
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024 08:57 ET
|
SciSparc Ltd
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s MEAI ...
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024 08:20 ET
|
SciSparc Ltd
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024 07:07 ET
|
SciSparc Ltd
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024 11:55 ET
|
SciSparc Ltd
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and...